Skip to main navigation
Akero
  • Contact
  • Linked
  • Twitter
  • About
    • Our Company
    • Our History
    • Leadership
    • Contact
  • Focus
    • Therapeutic Areas
    • Publications & Posters
  • Pipeline
    • Development Pipeline
    • Efruxifermin (EFX)
    • Research Programs
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access Policy
  • Careers
    • Our Culture
    • Job Opportunities
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Contact IR
Select Page
Akero
    • About
      • Our Company
      • Our History
      • Leadership
      • Contact
    • Focus
      • Therapeutic Areas
      • Publications & Posters
    • Pipeline
      • Development Pipeline
      • Efruxifermin (EFX)
      • Research Programs
    • Clinical Trials
      • Clinical Trials Overview
      • Expanded Access Policy
    • Careers
      • Our Culture
      • Job Opportunities
    • Investors & Media
      • Corporate Profile
      • Press Releases
      • Events & Presentations
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historic Price Lookup
        • Analyst Coverage
      • SEC Filings
      • Corporate Governance
        • Documents & Charters
        • Management Team
        • Board of Directors
        • Committee Composition
      • Investor Resources
        • Investor FAQs
        • Investor Email Alerts
        • Contact IR
    • Linked
    • Twitter
Hero-banner

Press Releases

Hero-banner
May 06, 2022
Akero Therapeutics Reports First Quarter 2022 Financial Results
May 02, 2022
Akero Therapeutics to Present at Upcoming Healthcare Conferences in May
Feb 25, 2022
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 08, 2022
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
Jan 04, 2022
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
  • About
  • Our Company
  • Our History
  • Leadership
  • Contact
  • Focus
  • Therapeutic Areas
  • Publications & Posters
  • Pipeline
  • Development Pipeline
  • Efruxifermin (EFX)
  • Research Programs
  • Clinical Trials
  • Clinical Trials Overview
  • Expanded Access Policy
  • Careers
  • Our Culture
  • Job Opportunities
  • Investors & Media
  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor Resources
Footer logo
©2021 Akero Therapeutics, Inc.
  • Privacy Policy
  • Terms of Use
  • Linked
  • Twitter